STAAR Surgical Company (STAA)

Return on equity (ROE)

Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Net income (ttm) US$ in thousands 21,347 19,444 24,889 31,863 38,755 37,824 33,582 29,111 24,501 22,906 20,778 11,039 5,913 8,965 7,461 12,547 14,048 8,765 7,836 5,752
Total stockholders’ equity US$ in thousands 385,954 378,595 357,617 338,924 336,112 323,142 302,317 276,317 261,568 249,108 234,622 214,176 197,222 186,392 174,674 164,967 159,884 149,340 144,335 137,338
ROE 5.53% 5.14% 6.96% 9.40% 11.53% 11.71% 11.11% 10.54% 9.37% 9.20% 8.86% 5.15% 3.00% 4.81% 4.27% 7.61% 8.79% 5.87% 5.43% 4.19%

December 31, 2023 calculation

ROE = Net income (ttm) ÷ Total stockholders’ equity
= $21,347K ÷ $385,954K
= 5.53%

STAAR Surgical Company's return on equity (ROE) has exhibited some fluctuations over the past few quarters. The ROE values ranged from 3.00% to 11.71% in the given periods.

In general, a higher ROE indicates that the company is generating more profit with the shareholders' equity. The upward trend in ROE from 5.43% in March 2019 to 11.71% in September 2022 suggests an improvement in the company's profitability and efficiency in using shareholders' equity to generate earnings.

However, the ROE dropped to 5.53% by the end of December 2023. This decrease in ROE could be a concern and would require further analysis to understand the factors contributing to the decline in profitability. It is essential for investors and stakeholders to closely monitor the company's financial performance and management's strategies to ensure sustained profitability and value creation.


Peer comparison

Dec 31, 2023